Introduction
Oral implants are widely accepted in dental medicine as a reconstructive treatment modality for tooth replacement due to disease, injury or congenital defects. In clinical situations exhibiting limited alveolar bone availability, growth factor application has been advocated to improve osteogenesis and osseointegration. 1 However, as a result of the transient action and the high degradation rate of recombinant proteins in vivo, 2 the sustained bioactivity of gene therapy vectors has been purported to be an effective alternative for the delivery of growth factor proteins. 3, 4 Adenoviral (Ad) vectors have been shown to exhibit a high in vivo transduction efficiency, 5 with a relatively short expression period compared with other viral-based gene delivery methods, and their effectiveness for promoting initial wound healing without eliciting long-term health concerns in wound healing models). 6, 7 Platelet-derived growth factor (PDGF) is a potent mitogen that facilitates wound healing 8 and stimulates bone repair by expanding osteoblastic precursor cells. 9, 10 PDGF-BB is Food and Drug Administration-approved for use in the treatment of localized periodontal defects and diabetic ulcers [11] [12] [13] Ad-mediated PDGF-B (Ad-PDGF-B) gene delivery has been shown to enhance periodontal tissue regeneration of tooth-supporting wounds. 6, 14 Limited information is available regarding the potential of PDGF-BB on promoting osseointegration of oral implants. In addition, the influence of PDGF-B on the mechanical integrity of an implant interface is unknown. The purpose of this study was to investigate the effects of rhPDGF-BB and Ad-PDGF-B delivered in a collagen matrix on the osteogenesis and osseointegration of dental implants in an in vivo osseointegration model. This approach shows the ability of Ad-PDGF-B to accelerate oral implant osseointegration. The data support the concept that Ad-PDGF-B gene delivery may be an effective and safe mode of therapy comparable with PDGF-BB application to promote dental implant osseointegration and oral bone repair.
Results

Ad-PDGF-B and rhPDGF-BB enhance osteogenesis in vivo
On the basis of the descriptive histology (Figure 1a ), by day 10 a gradual defect resolution was observed over time in all groups. At days 10 and 14, woven bone and primary trabecular bone were noted at the coronal margin (red asterisks) in Ad-Luc-treated specimens, and thicker bone trabeculae and defect fill (DF) were evident in all PDGF-treated specimens (black asterisks in 5.5 Â 10 8 and 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B, and rhPDGF-BB). Also at day 14, more mature bone apposition and near-complete DF were noted for all PDGF-treated specimens (Figure 1a , lower panel). The histomorphometric measurements of the 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B and rhPDGF-BB groups showed significantly higher bone-implant contact (BIC) than the Ad-Luc group at day 10 (Po0.05, Figure 1b ). Furthermore, all PDGF groups indicated higher DF than the Ad-Luc group at days 10 (Po0.01, Figure 1c ) and 14 (Po0.05, Figure 1c ). An equivalent defect repair pattern was noted from the backscattered scanning electron microscopy (BS-SEM) images (Figure 2a ). At day 10, BS-SEM measurements also showed a significant difference among all PDGF-treated groups compared with the Ad-Luc-treated group in both bone-area fraction (BAF, Po0.05, Figure 2b ) and tissue mineral density (TMD, Po0.05, Figure 1 Histological view of each group for 10 and 14 days (a) and two-dimensional evaluations; bone-to-implant contact (BIC) (b) and defect fill (c). (a) Histological images were overlapped by fluorescent images made by calcein injection 3 days after surgery. The fluorescence indicates the original defect boundaries. The results of Ad-Luc defects shows sparse bone formation at day 10 and a lesser degree of bone maturation at 10 and 14 days. All the PDGF-related specimens showed increased new bone formation at 10 and 14 days compared with the Ad-Luc group. Scale bar ¼ 200 mm (top right panel), original magnification, Â 40. (b) In BIC analysis, 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B and rhPDGF-BB groups showed significantly higher ratio than the control group at 10 days, and 5.5 Â 10 9 pfu ml in top right panel represents Ad-PDGF-B showed significantly higher ratio than the control group at 14 days. (c) In defect fill analysis, all three PDGF treatment groups showed higher fractions than Ad-Luc-treated defects at 10 and 14 days. Black area in left side: dental implant; black asterisks: matured new bone; red asterisks: young new bone; and dashed line: borders of the osseous defect. Data are presented as mean and bars indicate standard error measurement (n ¼ 6-8). *Po0.05, **Po0.01, Abbreviation: BIC: bone to implant contact.
PDGF promotes dental implant osseointegration P-C Chang et al Figure 2c ). A significant difference between rhPDGF-BB and Ad-Luc groups in TMD was also noted at day 14 (Po0.05, Figure 3c ). Completion of the DF was noted in all the animals by day 21, and no significant differences for any BS-SEM or histomorphometric parameters could be found among all the groups (data not shown).
Both Ad-PDGF-B and rhPDGF-BB promote osseointegration
The consequence of push-out testing was reflected from the osseointegration index (OI), with all PDGF-treated specimens showing higher scores than Ad-Luc, with significant differences noted between rhPDGF-BB and Ad-Luc at both days 10 and 14 (Po0.05, Figure 3a ). PDGF application tended to improve the interfacial stiffness (IS) and maximum removal loading (MRL) compared with the Ad-Luc group. The rhPDGF-BB treatment indicated significantly higher IS than all other groups at days 10 and 14 (Po0.05, Figure 3b ), and higher MRL than all other groups at day 10 (Po0.05, Figure 3c ). At day 14, the MRL of rhPDGF-BB was significantly higher compared with both the Ad-Luc and the 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B groups (Po0.05, Figure 3c ). Significant improvement of IS using 5.5 Â 10 8 pfu ml À1 Ad-PDGF-B treatment versus Ad-Luc (Po0.05, Figure 3b ) The three PDGF treatment groups showed a significant difference in bone area fraction at 10 days compared with the control group. (c) The three PDGF groups also showed significant differences in tissue mineral density at 10 days and the rhPDGF-BB group showed significance at 14 days compared with Ad-Luc defects. Data are presented as mean and bars indicate standard error measurement (n ¼ 6-8). *Po0.05.
PDGF promotes dental implant osseointegration P-C Chang et al was also seen at day 10. Most day 21 specimens experienced cortical bone fractures during the push-out testing (suggestive of strong osseointegration), and no significant differences among all the groups in IS and OI scores were noted (data not shown). Micro-computed tomography (micro-CT) images were analyzed after implant removal, and both the 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B and rhPDGF-BB groups showed significantly higher bone volume fraction (BVF) and TMD than the 5.5 Â 10 8 pfu ml À1 Ad-PDGF-B and Ad-Luc groups at day 10 (Po0.05, Figure 3d and e). A significant difference in BVF was found between 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B and Ad-Luc groups at day 14 (Po0.05, Figure 3d ). Both the 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B and rhPDGF-BB groups showed equivalent extents of functional composite tissue apparent modulus (FCAM), which was significantly stiffer than the 5.5 Â 10 8 pfu ml À1 Ad-PDGF-B or Ad-Luc group at day 10 (Po0.05, Figure 3f ). At day 14, there were no FCAM differences between any of the treatment groups.
Local delivery of Ad-PDGF-B shows acceptable safety profiles in vivo
In a separate study of systemic safety, animals were treated with collagen alone (control) or collagen containing Ad-PDGF-B (5.5 Â 10 8 or 5.5 Â 10 9 pfu ml À1 ). Blood samples were taken at various time points for hematological and clinical chemistry analyses and PCR analyses for vector sequence. All animals survived until the day of killing, with no progressive swelling or symptoms noted.
The majority of hematological and clinical chemistry parameters were within their normal ranges with no significant differences between Ad-PDGF-B and collagen-only treatments ( Tables 1 and 2) .
Vector-specific quantitative PCR 6 was carried out on blood samples taken at baseline, days 1, 2, 3, 4, 5, 7, 14, 21, 28, and 35 after treatment. Ad-PDGF-B was not detected in the bloodstream over the 35-day observation period (data not shown).
Discussion
This study shows that both Ad-PDGF-B gene and rhPDGF-BB protein delivery promote the acceleration of neo-osteogenesis of peri-implant bony defects in vivo. The effect on bone apposition was examined through DF from histomorphometry (Figure 1c ), BAF from BS-SEM ( Figure 2b ) and BVF from micro-CT ( Figure 3d ). From these results, all treatment groups, especially the 5.5 Â 10 9 pfu/ml Ad-PDGF-B and rhPDGF-BB groups, showed significantly greater bone formation compared with the Ad-Luc vector control group at 10 days. Regarding bone maturation, the Ad-Luc-treated defects showed sparse and limited new bone formation and slower bone formation within the defect area compared with the other three groups. By day 14, in the Ad-Luc group, new bone near the base of the defect (Figure 1a ) showed thick trabeculae and bone marrow formation, suggesting greater maturation, whereas the thin trabeculae and primary woven bone-like structures at the coronal portion of the defects suggests early-stage Osseointegration index (a), interfacial stiffness (b), and maximum removing load (c) showed significant differences between rhPDGF-BB treatment and the other three groups. Bone volume fractions (d), tissue mineral density (e) and functional tissue modulus (f) show that 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B and rhPDGF-BB groups showed significant differences compared with the 5.5 Â 10 8 pfu ml À1 AD-PDGF-B and Ad-Luc groups. There were no significant differences in tissue mineral density and functional composite tissue apparent modulus (FCAM) at day 14. Data are presented as mean and bars indicate standard error measurement (n ¼ 6-8). *Po0.05.
PDGF promotes dental implant osseointegration P-C Chang et al PDGF promotes dental implant osseointegration P-C Chang et al osteogenesis. However, in all PDGF-treated groups, advanced bone maturation throughout the defect area, especially in the higher dose Ad-PDGF-B and rhPDGF-BB groups, indicates that new bone formation initiated earlier in those two groups compared with controls. Taken together, these results strongly suggest that PDGF delivery, through both the protein and the gene transfer vector, significantly accelerated and enhanced new bone formation in the peri-implant defects, and the higher dose of Ad-PDGF-B showed more favorable results than lower dosage, suggesting a dose-dependent effect on osseointegration.
We also presented FCAM predicting the functional contribution of the newly-formed bone through the FE optimization procedures. 15 It is more correlated with the implant interfacial resistance than any single structural parameter. Significantly, higher FCAM from the 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B and rhPDGF-BB treatment groups at day 10 indicates that both PDGF protein and gene delivery stimulate not only osteogenesis but also favorable initial implant function.
Two-and three-dimensional quantification results between rhPDGF-BB and higher dose Ad-PDGF-B were also comparable (Figures 1-3) . However, the biomechanical analyses did not show equivalent trends, whereas rhPDGF-BB showed significant improvements compared with Ad-Luc for most of the parameters (Figure 3a-c) . Although the correlation between implant stability and peri-implant structures had been proven in previous research, 16, 17 this finding may be due to the different delivery profile of PDGF by either Ad or as a protein.
Although the initial response to a bolus administration of rhPDGF-BB may be robust, the protein's short half-life results in rapid degradation within a few days, 2 and a decrease in the mitogenic response. In contrast, Ad-PDGF-B delivery shows a delayed PDGF-BB expression profile that gradually decreases to B20% of the highest level by day 14 in vivo. 14 This finding is consistent with a previous report whereby Ad-PDGF-B prolongs PDGF signaling, leading to a delay with respect to timing of osteogenic differentiation. 18 The effects of PDGF on osseous wound healing have been reported mechanistically in previous investigations. It had been shown that PDGF signaling is important for chemotaxis and proliferation of osteoblasts and fibroblasts. 19, 20 However, PDGF's ability to induce osteogenic lineage differentiation is less clear. Tokunaga et al. 21 reported that PDGFRb signaling strongly inhibited osteogenic differentiation of mesenchymal stem cells, and Kono et al. 22 further validated that the Erk signaling, which is the subsequent PDGFR pathway, negatively regulated osteogenesis. On the other hand, other evidence implies that PDGF contributes to osteogenic differentiation through a more downstream mechanism. Huang et al. 23 detected PDGF mRNA expression at both the early proliferation stage and a late differentiation stage of osteoprogenitor cells. Furthermore, Ng et al. 24 showed that PDGFR activation was a key step for the osteogenic lineage differentiation of mesenchymal stem cells, whereas inhibition of PDGFbR resulted in decreased mineralized nodule formation. Kratchmarova et al. 25 reported that PDGF increased new bone formation in vivo despite limited influences in osteogenic differentiation in vitro. These results imply that the differentiation is promoted at a certain level of expression, such as dose-or time-dependent reactions. 19, 20 De Donatis et al. 19 reported that a higher concentration of PDGF is favorable for mitogenesis and lower doses for cell motility. Hsieh and Graves 20 found that pulse application of PDGF enhances bone formation, but prolonged exposure to PDGF limited in vitro bone regeneration. As osteogenesis involves a cascade of events in vivo, varying strategies of PDGF delivery must be considered for different indications. Thus, the rhPDGF-BB treatment may be suitable for the needs of rapid bone fill, where it would quickly recruit cells without significantly affecting the time frame of subsequent differentiation (Supplementary Figure 1a) . The higher dose of Ad-PDGF-B may be a better choice for a large wound site (that remains to be tested), in which the sustained PDGF signal would attract cell progenitors for a more extended, but still limited period of time so that the differentiation and maturation would initiate after PDGF signaling subsided (Supplementary Figure  1b) . Given the limited size of the rat maxilla and the high cell proliferative activity, it is necessary to further validate this assumption in a large animal model with more challenging, critical-size defects.
This use of gene therapy introduced a different strategy when compared with traditional scaffoldgrowth factor delivery. In our approach, the main function of the gene-activated matrix (that is, collagen matrix) was to mobilize the vector and allow for cell invasion. 26 The vector is then actively transfected into the cells, followed by disintegration of capsid, condensed by the adenovirus core proteins to enter the nucleus (o40 nm diameter) for the subsequent expression of the carrier gene. 27 Thus, the rate-limiting step of gene delivery was the vector transduction. High levels of adenovirus transduction within the first 2 weeks of delivery, and favorable regenerative effects have been documented in several studies. 6, 14, 28 Further efforts on the condensation of adenovirus vector may be beneficial for amplifying the efficiency of the gene therapy. 27 The angiogenic effect of PDGF, which are similar to the effect of vascular endothelial growth factor, may also be favorable for osseous wound repair. During wound healing, angiogenesis is an important event for new tissue regeneration (that is, providing nutrients and essential signals). The PDGFs have a similar structure to vascular endothelial growth factor, 29 and PDGF-BB enhances fibroblast growth factor-2 stimulated vascular endothelial growth factor release. 30 PDGFRb also has an important role in angiogenesis. 31 Therefore, it is reasonable to conclude that PDGF-BB also positively affects angiogenesis and ultimately contributes to bone formation. Considering that dental implant function (with a metallic non-vascularized interface) is largely dependent on the surrounding bone quantity, quality and the wound healing microenvironment, these accelerating and enhancing bone formation effects of PDGF may promote greater bone volume for earlier implant placement and loading.
One important consideration with the use of gene therapy vectors is the potential immune response and related sequelae. 32, 33 In our study, Ad-PDGF-B was delivered in a collagen matrix, which potentially masks the host immune function against Ad vectors in vivo. 28, 18, 26, 34 Typically, transformation and self-replication is eliminated by removing the E1-and E3-gene regions of the adenovirus genome. 35 We discovered no PDGF promotes dental implant osseointegration P-C Chang et al significant vector dissemination or alteration of hematological and clinical chemistry parameters. Our results showed a favorable preclinical safety profile and was comparable with our previous investigation examining Ad-PDGF-B in periodontal defects. 6 Furthermore, a nonviral-based vector might be an alternative for delivering the PDGF-B gene with minimal safety concerns. However, further efforts on the improvement of efficient delivery and expression of the non-viral vectors is still necessary. 36, 37 In summary, this investigation indicates the first reported use of Ad-PDGF-B administration to promote alveolar bone repair and osseointegration in alveolar ridge defects. These findings suggest that Ad-PDGF-B stimulates osseointegration that is comparable with the delivery of PDGF-BB protein. A good safety profile was shown supportive for extending this approach to large animal model studies examining large critical-size bony defects in the craniofacial complex.
Materials and methods
Experimental design
A total of 100 male Sprague-Dawley rats were used in this study and the general timeline is shown in Figure 4a . On the basis of the power analysis calculations from a similar study, 6-8 animals were analyzed per treatment per time point. 14 A rat dental implant osseointegration wound model was modified for the in vivo experiments. A total of 82 animals were used for evaluating the effects of osseointegration, with three time points (days 10, 14 and 21) and four treatment groups (5.5 Â 10 9 pfu ml À1 Ad-Luc as the control group, 5.5 Â 10 8 pfu ml À1 Ad-PDGF-BB, 5.5 Â 10 9 pfu ml À1 Ad-PDGF-BB and 0.3 mg ml À1 rhPDGF-BB) evaluated. In addition, 18 animals were equally divided into three treatment groups (collagen matrix alone as the control group, 5.5 Â 10 8 pfu ml À1 Ad-PDGF-BB and 5.5 Â 10 9 pfu ml À1 Ad-PDGF-BB) and used for determining the preclinical safety profile, with assessments performed on these same animals over an observation period of 35 days.
Ad vectors and recombinant protein
Ad-PDGF-B (E1-, E3-deleted adenovirus serotype 5 encoding human platelet-derived growth factor-B) and Ad-Luc (E1-, E3-deleted adenovirus serotype 5 encoding firefly luciferase) have been previously described. 6 In both vectors, transgene expression is under control of the CMV promoter. Titers of virus stocks were determined on embryonic kidney 293 cells by plaque assay and expressed as the particle number per milliliter. 7 The rhPDGF-BB was purchased from Biomimetic Therapeutics Inc. (Franklin, TN, USA) at a working concentration of 0.5 mg ml À1 .
Preparation of vector/protein-gene activated matrix
Ad-PDGF-B, Ad-Luc and rhPDGF-BB were dialyzed into GTS buffer (2.5% glycerol, 25 mM NaCl, 20 mM Tris, pH 8.0) and formulated in bovine fibrillar type I collagen matrix (Matrix Pharmaceutical Inc., Fremont, CA, USA) at a final concentration of 2.6%. Figure 4 Experimental design (a) and experimental model illustration (b). Implant surgery was performed 4 weeks following maxillary first molar extraction. To create a consistent and reproducible defect, custom-made step drills were used. After dental implant placement, the bone defect was filled with 5.5 Â 10 9 pfu ml À1 Ad-Luc, 5.5 Â 10 8 pfu ml À1 Ad-PDGF-B, 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B or 0.3 mg ml À1 rhPDGF-BB formulated with the collagen matrix for evaluating osseointegration (n ¼ 6-8 per group per time point). Histomorphometric and BS-SEM measurements were done at days 10, 14 and 21 after implant installation, and three-dimensional evaluations (micro-CT imaging) as well as functional assessments (biomechanical testing and functional simulations) were done at days 10, 14 and 21 after implant installation. For evaluating the safety profile, the bone defect was filled with 5.5 Â 10 8 pfu ml À1 Ad-PDGF-B, 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B or collagen matrix alone. The hematology, chemical chemistry and vector dissemination were evaluated over a period of 35 days (n ¼ 6 per group per time point).
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Animal model for evaluating therapeutic effects
All animal procedures followed the guidelines from the Committee on Use and Care of Animals of the University of Michigan. The maxillary first molars were extracted bilaterally 4 weeks before dental implant installation. After healing, an osteotomy was created using a custom drill-bit by a single surgeon (Y-JS). The drill-bit was designed with a 0.95-mm diameter, 1 mm long-apical portion and a 2.2-mm diameter, 1 mm long at the coronal aspect (Figure 4b) . The apical part of the drill created an osteotomy for initial fixation and the coronal part of the drill created a circumferential osseous defect before dental implant installation. A custom cylinder-type titanium miniimplant (kind gift of Institut Straumann AG, Basel, Switzerland), 1 mm in diameter and 2 mm in depth, was press-fit into the surgically created socket (Figure 4b ). The remaining defect was then filled with the type I collagen matrix containing 5.5 Â 10 9 pfu ml À1 Ad-Luc, 5.5 Â 10 8 pfu ml À1 Ad-PDGF-B, 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B or 0.3 mg ml À1 rhPDGF-BB (Figure 4b ). Ad-Luc has not previously exhibited biological activities in dentoalveolar defects 14 and served as a control group in this study. The surgical area was covered by gingival tissue and re-approximated using butyl cyanoacrylate (Periacryl, Glustitch Inc., Point Roberts, WA, USA). The vital fluorochrome dye, calcein (10 mg kg À1 ), was injected intramuscularly after 3 days, and antibiotics (268 mg l À1 ampicillin in 5% dextrose water) were provided during the first 7 days after operation.
BS-SEM and histology
Coded maxillae containing the implants were harvested upon killing, with one side of maxillae taken for BS-SEM and histology, whereas the contralateral maxillae were used for biomechanical assessments (see following section). The specimens were fixed in 50% ethanol for at least 72 h and subsequently embedded in epoxy resin. The specimens were then sectioned in the longitudinal direction relative to the implants using a diamond saw blade (Crystalite Co., Westerville OH, USA), then polished to achieve a 50-to 100-mm final thickness. The tissue mineralization was evaluated under the backscattered mode on Qanta F1B SEM with Â 45 magnification, calibrated with aluminum and carbon discs, 38 and transferred to physical density using bone substitute radiographic phantoms (Gammex Inc., Middleton WI, USA). The photographs were then segmented and threshholded by Otsu's adaptive technique. 39 To eliminate any metal scattering effect, the measured bone-implant interface was defined as the horizontal distance 5 mm from the outermost homogenous highintensity area. The defect borders were projected using the calcein fluorescent images. BAF (the ratio of newly formed bone in the defect to the entire defect area) and TMD within the defect (the average grayscale level of mineralized tissue within the defect area) were measured from BS-SEM images. Next, histological staining by methylene blue was performed, with the acid fuschin used as the counterstain. 28 BIC (the ratio of the length of bone contacting the titanium to the entire length of titanium interface with the defect area) and DF (the ratio of bone-occupied area to the entire defect area) were measured by calibrated examiners P-CC and Y-JS).
Biomechanical, three-dimensional radiographic and functional evaluations
The remaining maxillae were used for biomechanical and micro-CT evaluation and stored in normal saline at À20 1C to preserve the mechanical integrity. After thawing at room temperature, the specimens were rapidly secured in acrylic resin. The mini-implants were meticulously pushed out of each maxilla using an MTS machine (Model 858, Mini-Bionix II, MTS Systems Corp., Eden Prairie, MN, USA) at a constant displacement rate of 0.1 mm s À1 , while recording the load-displacement relationship of the top of implant during the push-out procedures. The region from 20 to 80% of the MRL was chosen and a linear regression was performed to calculate the IS. A previously described OI based on the nature of the bone fail during implant push-out tests was also used to further document the interfacial biomechanical behavior ( Supplementary Table S1 ). 15 After implant push-out, micro-CT scans were performed using an eXplore Locus SP Micro-CT system (GE HealthCare, London, ON, Canada) and reconstructed to the voxel size of 18 mm Â 18 mm Â 18 mm. The spatial relationship of the mini-implant and surrounding tissues was then analyzed using a customized MATLAB (Mathworks Inc., Natick, MA, USA) algorithm. The images were segmented with a threshold determined by Otsu's adaptive technique, 39 and several parameters were quantitatively evaluated within the osseous defect areas: (1) BVF: the volume of mineralized tissue within the osseous wound divided by the volume of osseous wound; (2) TMD: the mineral content of the radiographic-defined mineralized tissue within the osseous wound divided by the volume of osseous wound; (3) bone mineral density: the mineral density within the radiographic-defined mineralized tissue in the osseous wound. After micro-CT evaluations, the images were transferred to create a finite element (FE) mesh, and the functional bone modulus (referring to the rigidity of bone within the area of interest toward dental implant) and FCAM (rigidity of the whole tissue within the area of interest toward dental implant) were generated from previously described simulation procedures. 15 
Safety profile determination
A total of 18 male Sprague-Dawley rats had their first maxillary molars extracted, osseous defect created and implant placement as previously described. 28 The osseous defects were filled with the type I collagen vehicle alone, or containing Ad-PDGF-B (5.5 Â 10 8 or 5.5 Â 10 9 pfu ml À1 ). Another six animals without any surgical treatments were also included to provide baseline parameters. Blood was drawn from rat tail veins at baseline and at 1, 2, 3, 4, 5, 6, 7, 14, 21, 28 and 35 days. Hematological and clinical chemistry parameters (listed in Table 1 ) were examined at baseline and at 3, 7, 14, 21, 28 and 35 days. Vector dissemination was evaluated for all blood draw time points. Genomic DNA was isolated from 50 ml whole blood using QIAamp DNA Blood Mini kit (Qiagen Inc., Valencia, CA, USA), and quantitative TaqMan PCR was used to determine the copies of Ad-PDGF-B in the bloodstream. The primers used for qPCR bridging the vector backbone and PDGF-B prepro region were as follows: sense, 5 0 -GGATCTTCGAGTCGACA AGCTT-3 0 ; anti-sense, 5 0 -ATCTCATAAAGCTCCTCG PDGF promotes dental implant osseointegration P-C Chang et al GGAAT-3 0 ; and internal fluorogenic probe, 5 0 -CGC CCAGCAGCGATTCATGGTGAT-3 0 . The resulting amplicon was detected by ABI Prism 7700 sequence detection instrument (Applied Biosystems, Foster City, CA, USA), and the thermal condition was as follows: 50 1C for 2 min, 95 1C at 10 min followed by 45 cycles of 95 1C for 15 s and 60 1C for 1 min. The assay sensitivity was 30 copies per 500 ng DNA. There was no cross-reaction with Ad vector encoding PDGF-A, PDGF-1308 (dominantnegative, PDGF mutant), bone morphogenetic protein-7, noggin, bone sialoprotein, Ad-Luc or green fluorescent protein.
Statistical analysis
One-way ANOVA with Tukey test was used to analyze the difference of coded specimens for histomorphometric, BS-SEM, micro-CT, biomechanical and functional parameters between PDGF-treated (collagen containing 0.3 mg ml À1 rhPDGF-BB, 5.5 Â 10 8 or 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B) and non-PDGF-treated (collagen alone) groups at each time point. For evaluating the safety profile, the difference of vector replicates, hematological and chemical parameters between experimental groups (collagen containing 5.5 Â 10 8 or 5.5 Â 10 9 pfu ml À1 Ad-PDGF-B) were evaluated for time-dependent dynamics with the control (collagen alone) group using Bonferroni post-tests, and the significance was assessed by repeated-measures ANOVA. The statistical difference was considered with a P-value of o0.05.
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